Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience
Another Boost For AI
Executive Summary
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.
You may also be interested in...
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Bayer Switches Focus Of Recursion AI Pact To Oncology
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.